Antibody Content against Epstein-Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing-Remitting Multiple Sclerosis.
Epstein–Barr virus
antibodies
biomarker
extracellular vesicles
multiple sclerosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
received:
20
08
2023
revised:
08
09
2023
accepted:
13
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
We aimed to analyze whether EVs carry antibodies against EBV antigens and the possibility that they could serve as diagnostic and disease activity blood biomarkers in RRMS. This was a prospective and observational study including patients with RRMS with active and inactive disease and healthy controls. Blood EVs were isolated by precipitation. Titers of antibodies against nuclear (anti-EBNA1) and capsid (anti-VCA) EBV antigens in EVs and in plasma, as well as content of myelin antibodies in EVs were determined by ELISA. An exploratory analysis of correlations with clinical and radiological data was performed. Patients with RRMS had higher titers of anti-VCA inside EVs and free in plasma than healthy controls. Patients with active disease showed higher levels of anti-EBNA1 in EVs, but not in plasma, than patients with inactive disease. EV anti-VCA levels correlated with disease duration and with decreased brain volume structures-total brain, white matter, gray matter, cerebellum, hippocampus, -but not with T2/FLAIR lesion volume or EDSS, SDMT, or 9HPT. In addition, EV anti-VCA correlated with EV anti-MBP. The anti-VCA and anti-EBNA1 content in EVs could represent diagnostic and disease activity blood biomarkers, respectively, in RRMS.
Identifiants
pubmed: 37762495
pii: ijms241814192
doi: 10.3390/ijms241814192
pmc: PMC10531815
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Neurovirol. 2017 Apr;23(2):329-334
pubmed: 27878471
Transfusion. 2023 Mar;63(3):564-573
pubmed: 36722460
J Neuroimmunol. 2015 Aug 15;285:156-60
pubmed: 26198934
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Front Immunol. 2021 Mar 22;12:640935
pubmed: 33828551
Trends Mol Med. 2020 Mar;26(3):296-310
pubmed: 31862243
J Neurol. 2002 Apr;249(4):375-89
pubmed: 11967640
Front Immunol. 2020 Dec 17;11:587078
pubmed: 33391262
J Neuroimmunol. 2023 Apr 15;377:578064
pubmed: 36934525
Nature. 2022 Mar;603(7900):321-327
pubmed: 35073561
Mult Scler Relat Disord. 2021 Nov;56:103328
pubmed: 34666240
Int J Mol Sci. 2021 Aug 20;22(16):
pubmed: 34445717
Lancet Neurol. 2023 Apr;22(4):338-349
pubmed: 36764322
Front Immunol. 2023 Aug 10;14:1224217
pubmed: 37638059
J Exp Med. 2008 Aug 4;205(8):1763-73
pubmed: 18663124
Nat Rev Neurol. 2017 Jan;13(1):25-36
pubmed: 27934854
J Neuroimmunol. 2011 Jan;230(1-2):160-3
pubmed: 21109310
Vox Sang. 1999;77(1):17-23
pubmed: 10474086
J Neuroinflammation. 2014 Nov 13;11:188
pubmed: 25391491
Curr Protoc Cell Biol. 2020 Sep;88(1):e110
pubmed: 32633898
Mult Scler. 2020 Oct;26(11):1281-1297
pubmed: 32202208
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
J Exp Med. 2007 Nov 26;204(12):2899-912
pubmed: 17984305
J Neuropathol Exp Neurol. 2014 Jul;73(7):729-31
pubmed: 24918642
Trends Neurosci. 2019 May;42(5):361-372
pubmed: 30926143
Autoimmune Dis. 2012;2012:969657
pubmed: 22666554
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Mol Ther. 2021 Jun 2;29(6):1946-1957
pubmed: 33895328
J Neuroinflammation. 2018 Jan 16;15(1):18
pubmed: 29338732
J Neuropathol Exp Neurol. 2013 Jan;72(1):29-41
pubmed: 23242282
Stem Cell Res Ther. 2020 Feb 19;11(1):70
pubmed: 32075692
Front Immunol. 2022 Sep 14;13:991662
pubmed: 36189297
Nat Rev Neurol. 2023 Mar;19(3):160-171
pubmed: 36759741
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16955-16960
pubmed: 31375628
J Neurol Sci. 2000 Feb 1;173(1):32-9
pubmed: 10675577
J Neuroimmune Pharmacol. 2021 Sep;16(3):567-580
pubmed: 32808238